BASF has unleashed Pepsensyal, a synthetic peptide for skin care applications that has been clinically proven to reduce and delay the first visible signs of ageing.
Pepsensyal (INCI: Mannitol (and) Acetyl sh-Tetrapeptide-1 (and) Lauroyl sh-Tetrapeptide-1) has been launched in response to the slow-ageing trend, which reflects a shift in consumer attitudes.
Rather than fight the natural ageing process, consumers are increasingly concerned with healthy ageing through a holistic, preventative approach to skin care.
In recent years, peptides in particular have gained a lot of traction in the personal care market and are recognized by consumers as effective, science-backed ingredients.
Pepsensyal expands BASF's peptide portfolio with a new cost-effective variant. The new ingredient is free of preservatives and 99% of natural origin.
In a double-blind, randomized, split-face clinical trial with 32 women aged between 44 and 64, Pepsensyal at 0.2% was tested against a placebo product without the new ingredient.
After 14 days, crow's feet appeared smoother, with an 11% decrease in average roughness and a 14% decrease in maximum relief amplitude.
At the same time, skin isotropy increased by 15%, indicating a skin resurfacing effect.
In that same test, Pepsensyal was also proven to replenish the skin from the inside: after 28 days, the skin had re-densified, with a 21% increase in the echogenic surface area of the dermis.
Extensive in vitro testing has confirmed the ingredient's ability to support skin regeneration, helping to slow the visible signs of skin ageing.
